偏头痛急性发作期新兴治疗药物的研究进展

Research Progress of Emerging Therapeutic Drugs in the Acute Onset Period of Migraine

偏头痛是一种高度致残性神经血管性疾病,严重影响病人的工作和生活。以往,用于治疗偏头痛的急性药物包括镇痛药、非甾体抗炎药(NSAID)、阿片类、巴比妥酸盐、麦角衍生物和曲坦类,这些急性发作期药物治疗虽能快速止痛,但有较多不良反应的发生,部分患者出现拒绝服用的情况,因此更新治疗方案对偏头痛患者极为重要。本文从偏头痛病理生理机制出发,重点阐述血清素5-羟色胺1F受体激动剂(5-HT1F receptor agonists)及降钙素基因相关肽受体拮抗剂(CGRP receptor antagonists)等新型药物对偏头痛急性发作期治疗的研究,以期为临床医生提供更多、更佳的偏头痛治疗方案,提高患者的生活质量,降低患者及社会的经济负担。

Migraine is a highly disabling neurovascular disease that seriously affects the patient’s work and life. In the past, acute drugs were used to treat migraine including analgesics, non-steroidal anti- in-flammatory drugs (NSAID), opioids, barbiturate, erggot derivatives and triptan. These acute onset drug treatments can quickly pain, but there are more adverse reactions. Some patients refused to take it, so updating the treatment plan is very important for migraine patients. Based on the path-ophysiological mechanism of migraine, it focuses on the study of novel drugs such as serotonin 5-HT1F receptor agonists and CGRP receptor antagonists in the treatment of acute migraine attacks, in order to provide more and better treatment options for migraine, improve the quality of life and reduce the economic burden of patients and society.